PGX for Pharmacists Pharmacy Podcast Network

Pharmacogenomics consulting isn't the glamorous and highly lucrative career path some voices in the pharmacogenomics industry portray it to be... In this episode, Behnaz and Becky dispel the "get rich quick" myth about PGx and discuss what pharmacists need to know “beyond the PGX certificate” to be successful creating a career in pharmacogenomics as they have. So, don't quit your full time pharmacist job to become a pharmacogenomics consultant until you listen to this enlightening episode of the PGx for Pharmacists Podcast! https://cpicpgx.org/

In this episode of the PGx for Pharmacists Podcast, Behnaz and Becky take a break from interviewing other pharmacogenomics experts and share their expert opinions on current pressing issues and future projections for the pharmacogenomics industry. In addition, Behnaz and Becky drop a few hints on what listeners can look forward to from the PGx for Pharmacists Podcast starting in 2023.
www.stoplabcuts.org
www.cap.org/member-resources/articles/message-from-the-cap-president-on-the-valid-act
 

Dr. Lucas Berenbrok is a pharmacist educator and researcher at the University of Pittsburgh School of Pharmacy in Pittsburgh, Pennsylvania. He co-led the implementation of outpatient pharmacogenomic services at University of Pittsburg Medical Center. This unique service, called Primary Care Precision Medicine, provides pharmacogenetic and genetic testing to patients in local and surrounding areas. With his colleagues at the University of Pittsburgh, Berenbrok co-created Test2LearnTM, a pharmacogenomics certificate program for pharmacists. Dr. Neda Leonard, CEO of Rx Gene IQ and she is a Dual Board-Certified Pharmacist in Pharmacotherapy and Geriatrics. She has experience in various setting such as Program for All-inclusive Care for Elderly (PACE) where she uses her expertise in medication management and PGx.
She is a seasoned speaker locally and nationally on various subject matters such as pharmacogenomics and polypharmacy. She has published in Drug Metabolism Reviews and was featured in THE CONSULTANT PHARMCIST Journal. Currently she partners with a group of Geriatricians/Internal Medicine physicians using a collaborative practice agreement for patients living independently, in assisted living facilities or in skilled nursing facilities. She has many tools in her toolbox to use such as pharmacogenomics, deprescribing, geriatric medication optimization, Part D Comprehensive Medication Management (CMR) and Targeted Medication Review (TMR),and working with various private insurances such as United Healthcare and Optum.

A Multidisciplinary Precision Medicine Service in Primary Care www.ncbi.nlm.nih.gov/pmc/articles/PMC8786423/
Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Larry Shapiro is a clinical psychologist that started back in 1990 but quote on quote retired to become a financial advisor. He was having a discussion with his brother one day, who was a career officer in the Army, returning from Afghanistan. That make Dr. Shapiro to re-think about his contributions to his community, so he got his license back, trained in military trauma, and started again as a psychologist in 2014. He started at St. Louis Behavioral Medicine Institute specializing in treatment of OCD, panic disorder, social anxiety disorder, simple phobias, depression, and combat trauma. Last year he attended the annual Boston Trauma Conference and heard for the first time about the use of psychedelic medicines for treatment of trauma. So after a 150 hour certification program at Integrative Psychiatry Institute he became certified in psychedelic-assisted psychotherapy which now is part of his current practice. Just this year in January he went into private practice so he can focus more on psychedelics. He is also an adjunct instructor in the department of psychiatry at Washington University in St. Louis and a clinical consultant for psilocybin research at Healthy Minds Lab at Washington University.
Post-traumatic stress disorder (PTSD) which is one of the most common psychiatric disorders which affects about 8 million adults at some point in their lifetime in the United States. But it is not clear as to why only some people who experience a traumatic event develop PTSD. Some people say it’s a social construct but in the largest and most diverse genetic study of PTSD to date, scientists from University of California San Diego School of Medicine and more than 130 additional institutions participating in the Psychiatric Genomics Consortium found that PTSD has a strong genetic component similar to other psychiatric disorders. Genetics seem to accounts for between 5 and 20 percent of the variability in PTSD risk following a traumatic event.

Resources: https://health.ucsd.edu/news/releases/Pages/2019-10-08-study-reveals-ptsd-has-strong-genetic-component.aspx
Learn more about your ad choices. Visit megaphone.fm/adchoices

Significant challenges to widescale clinical implementation of PGx include a lack of physician experience using PGx test data or confidence in interpreting PGx test data and integrating the data into the medication therapy management process. For PGx to be most impactful, prescribers must consider PGx data within the context of other non-genetic patient-specific factors. Pharmacists may help prescribers with PGx test data by creating a summary of medication therapy management recommendations for the patient that streamlines PGx report flags and identifies other pharmacotherapy interventions the pharmacist recognizes while applying non-genetic patient-specific data to the PGx test data.

In this episode of the PGx for Pharmacists podcast, Dr. Becky Winslow discusses the research study, "Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation," with two of the research investigators, Dr. Anna Langerveld and Dr. David Bright. Dr. Langerveld and Dr. Bright share how this research adds to the growing evidence that clinical pharmacists can help improve the utility of PGx and prescribing. They also share how their study described a process for reducing PGx laboratory report information to a single page of patient-specific clinical recommendations. Lastly, they share that while clinical decision support tools are becoming more routine for pharmacogenomic management, the pharmacists in this study reduced the number of report-based alerts independent of sophisticated clinical decision support informatics.

Anna Langerveld, Ph.D., is the Founder and President of Genemarkers, a contract research organization and CLIA/CAP certified testing laboratory specializing in genomics. Anna received her B.A. in Psychology from SUNY Binghamton and her Ph.D. from the Interdisciplinary Program in Neurosciences at Tulane University. After receiving her Ph.D., Anna served as a Research Assistant Professor at Western Michigan University. She founded Genemarkers in 2008. Under her leadership, Michigan Celebrates Small Business recognized the Company as one of the Top 50 Michigan Companies to watch.
Anna is an author of peer-reviewed publications, an NIH grant recipient, and an invited speaker at a wide range of national meetings. Anna currently serves as an adjunct professor and an advisory board member for the Manchester University pharmacogenomics program and holds a community faculty position at the Western Michigan University Homer Stryker M.D. School of Medicine.
Anna has been instrumental in developing strategic community partnerships to implement the use of genomics in clinical care, with a particular focus on mental health and underserved populations.

Dr. David Bright is a Professor of Pharmacy at Ferris State University, where he has taught therapeutics and medication therapy management. He received his PharmD degree from the University of Toledo, completed a community pharmacy residency with Kroger Pharmacy and the University of Toledo, and served on the faculty at the Ohio Northern University as a community pharmacy residency program director. His research has primarily involved the pragmatic implementation and improvement of non-dispensing pharmacy services, particularly in the outpatient setting. Most recently, that has involved the integration of pharmacogenomics into clinical practice through community pharmacy and ambulatory care practice models.

Research discussed in the podcast episode:
Bright D, Saadeh C, DeVuyst-Miller S, Sohn M, Choker A, Langerveld A. Pharmacist Consult Reports to Support Pharmacogenomics Report Interpretation. Pharmgenomics Pers Med. 2020 Dec 10;13:719-724. doi: 10.2147/PGPM.S276687. PMID: 33328756; PMCID: PMC7735940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735940/
Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Sandra Awaida is a clinical pharmacist that has been practicing in the US since 1999. She worked as an attending pharmacist at the Massachusetts General hospital which is a Harvard Medical School teaching hospital in the intensive care unit and internal medicine department where she also served on the pharmacy residency advisory committee, the MGH pharmacy research committee and a writer to the MGH pharmacy newsletter. She joined Novartis Canada working on new product launches, developing medical content and speaking on national meetings. Her passion for clinical pharmacy led her on to teach at several universities in the US and abroad until she found her calling when she founded a private cardiology practice where she incorporated Chronic Care Management, Remote Patient Monitoring or RPM and PGx. She is the founder of PreciGenX, LLC. Since 2008, she has worked to advance the non traditional role of pharmacists in medical practices and is a is a huge advocate of a preventative approach to patient care. She is constantly looking to create value by marrying cutting-edge innovative services with the highest evidence-based medicine to achieve the best outcome for her patients and increase ROI or Return of Investment for physicians. And of course she has been mentoring and coaching others to be able to do the same.
Learn more about your ad choices. Visit megaphone.fm/adchoices